Ilumya (tildrakizumab) vs Skyrizi (risankizumab)
Ilumya (tildrakizumab) vs Skyrizi (risankizumab)
Ilumya (tildrakizumab) and Skyrizi (risankizumab) are both biologic medications approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Ilumya works by targeting interleukin-23 (IL-23), a cytokine involved in inflammatory processes, and is administered every 12 weeks after initial doses at weeks 0 and 4. Skyrizi also targets IL-23 but is administered more frequently, with initial doses at weeks 0 and 4, followed by dosing every 12 weeks, and may offer a different efficacy and safety profile, which should be discussed with a healthcare provider to determine the most suitable option based on individual patient needs and medical history.
Difference between Ilumya and Skyrizi
Metric | Ilumya (tildrakizumab) | Skyrizi (risankizumab) |
---|---|---|
Generic name | Tildrakizumab | Risankizumab |
Indications | Plaque psoriasis | Plaque psoriasis, Psoriatic arthritis |
Mechanism of action | IL-23 inhibitor | IL-23 inhibitor |
Brand names | Ilumya | Skyrizi |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Upper respiratory infections, injection site reactions, diarrhea | Upper respiratory infections, headache, fatigue, injection site reactions |
Contraindications | Hypersensitivity to active or inactive ingredients | Hypersensitivity to active or inactive ingredients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Sun Pharma | AbbVie |
Efficacy
Efficacy of Ilumya (Tildrakizumab) for Psoriasis
Ilumya, with the active ingredient tildrakizumab, is a biologic medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory processes and linked to psoriasis pathogenesis. Clinical trials have demonstrated that Ilumya is effective in achieving significant skin clearance. In pivotal Phase III trials (reSURFACE 1 and reSURFACE 2), a substantial proportion of patients treated with Ilumya achieved at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score, which is a common measure of psoriasis severity.
Furthermore, many patients treated with Ilumya experienced a PASI 90 response, indicating a 90% reduction in PASI score from baseline, signifying near-complete skin clearance. The long-term efficacy of Ilumya has also been supported, with sustained responses observed in patients over a period of several years. The safety profile of Ilumya was found to be favorable, with low rates of serious adverse events, which is an important consideration for long-term management of psoriasis.
Efficacy of Skyrizi (Risankizumab) for Psoriasis
Skyrizi, containing the active substance risankizumab, is another biologic therapy approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Risankizumab is a monoclonal antibody that selectively inhibits IL-23 by binding to its p19 subunit, similar to tildrakizumab. Skyrizi has shown high efficacy in clinical studies, with a significant number of patients achieving clear or almost clear skin. In Phase III trials, such as UltIMMa-1 and UltIMMa-2, Skyrizi demonstrated superior efficacy in achieving PASI 90 and PASI 100 responses compared to placebo and other comparator treatments, including ustekinumab, another IL-12/23 inhibitor.
The efficacy of Skyrizi was not only rapid but also durable, with many patients maintaining skin clearance over time. The UltIMMa trials reported that a majority of patients receiving Skyrizi maintained PASI 90 and PASI 100 responses at one year. The safety profile of Skyrizi was also favorable, with a low incidence of serious adverse events, which is consistent with the safety profiles of other IL-23 inhibitors. The robust efficacy and safety data support the use of Skyrizi as a valuable treatment option for patients with moderate-to-severe plaque psoriasis.
Regulatory Agency Approvals
Ilumya
Skyrizi
Access Ilumya or Skyrizi today
If Ilumya or Skyrizi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us